Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Johanna Lister,1 Sanja Stanisic,1 Klaus Kaier,2 Christian Hagist,2 Dmitry Gultyaev,1 Stefan Walzer31Analytica LA-SER International Inc, L&ouml;rrach, Germany; 2Research Centre for Generational Contracts, University of Freiburg, Freiburg, Germany; 3F Hoffmann-La Roche Ltd, Pharmaceuticals Div...

Full description

Bibliographic Details
Main Authors:	Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-10-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/societal-savings-in-patients-with-advanced-non-squamous-non-small-cell-a11168

Similar Items

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
by: Andrés Felipe Cardona, et al.
Published: (2016-01-01)

Application of Bevacizumab in Non-small Cell Lung Cancer
by: Ping XU, et al.
Published: (2017-04-01)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
by: Toshiaki Yoshimoto, et al.
Published: (2020-03-01)

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation
by: Yanjuan Xiong, et al.
Published: (2024-10-01)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
by: Jing Wang, et al.
Published: (2023-04-01)

Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
by: Geoffroy Bilger, et al.
Published: (2022-05-01)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
by: Mototsugu Shimokawa, et al.
Published: (2022-02-01)

Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.
by: Yusuke Takagi, et al.
Published: (2013-01-01)

Development of bevacizumab-conjugated ferromagnetic nanoparticles for non-invasive angiogenesis detection
by: Bouziotis, P, et al.
Published: (2009)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
by: Takashi Kasai, et al.
Published: (2023-07-01)

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
by: Yuankai Shi, et al.
Published: (2021-09-01)

SUCCESSFUL REGISTRATION OF DOMESTIC BIOANALOGUE OF BEVACIZUMAB – NEW OPPORTUNITIES FOR EFFECTIVE TREA TMENT OF PATIENTS WITH NON-SQUAMOUS CELL NON-SMALL CELL LUNG CANCER
by: S. V. Orlov, et al.
Published: (2016-01-01)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
by: Ni Jun, et al.
Published: (2020-07-01)

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
by: Shohei Hamada, et al.
Published: (2019-04-01)

Intravitreal bevacizumab
by: Bakulesh M Khamar
Published: (2018-01-01)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015-12-01)

Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizuma
by: Kanwal Zareen Abbasi
Published: (2016-03-01)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
by: Chien C-R, et al.
Published: (2012-07-01)

Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: Is there an association?
by: Bodla Ali, et al.
Published: (2010-01-01)

Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris
by: Jonathan C. Schell, et al.
Published: (2011-05-01)

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye
by: Mohammadreza Peyman, et al.
Published: (2019-03-01)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
by: Zhiting Zhao, et al.
Published: (2023-01-01)

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
by: Yahua Wu, et al.
Published: (2023-12-01)

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)
by: Takeda Masayuki, et al.
Published: (2012-08-01)

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
by: Zhuo Ye, et al.
Published: (2015-08-01)

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
by: Satoshi Ikeda, et al.
Published: (2018-03-01)

A pilot trial of consolidation bevacizumab after hypo‐fractionated concurrent chemoradiotherapy in patients with unresectable locally advanced non‐squamous non‐small‐cell lung cancer
by: LanQing Huo, et al.
Published: (2023-09-01)

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
by: Florent Baty, et al.
Published: (2017-03-01)

Non-Surgical Management of Recurrent Naso-Orbital Hemangiomas with Bevacizumab: A Case Report
by: Liu S, et al.
Published: (2024-10-01)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
by: Benjamin K. Schneider, et al.
Published: (2019-08-01)

Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer
by: Bin AI, et al.
Published: (2020-07-01)

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer
by: Jie Xiao, et al.
Published: (2016-09-01)

Adverse Events Related to Bevacizumab and the Management Principles in Non-small Cell Lung Cancer
by: Gang CHENG, et al.
Published: (2010-06-01)

Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
by: Yujie LIU, et al.
Published: (2019-02-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-01-01)

Bevacizumab and ovarian cancer
by: Agustin Garcia, et al.
Published: (2013-03-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-06-01)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
by: Chen Chen, et al.
Published: (2021-11-01)

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
by: Rui Wan, et al.
Published: (2021-12-01)

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study
by: Wei Fang, et al.
Published: (2024-08-01)